Role of calcium channel blockers in reducing acute ischaemia and preventing restenosis in PTCA.
Calcium channel blockers (calcium antagonists) are widely used before, during and after percutaneous transluminal coronary angioplasty (PTCA). When administered during PTCA, calcium channel blockers may be beneficial in decreasing regional ischaemia in patients with proven or suspected variant angina, as a result of their cardioprotective effects, their ability to enhance collateral flow, and their antispastic effects at the epicardial level. More recently, the agents have also proven to be effective in patients who have developed "no-reflow' phenomenon during PTCA. Preliminary findings suggest that calcium channel blockers may also have potential benefits when administered after angioplasty. The combined results of 5 studies, evaluating a total of 919 patients, showed a trend towards angiographic reduction in restenosis. These observations are of interest but may be due to reporting bias. In conclusion, calcium channel blockers are effective in reducing ischaemia induced by PTCA. These agents may, thus, be appropriate in high risk patients. Further large studies examining the effects of calcium channel blockers on restenosis are required to confirm the observations available to date.
Vahanian
A
A
Service de Cardiologie, Hôpital Tenon, Paris, France.
Lung
B
B
D015906:Angioplasty, Balloon, Coronary; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D017202:Myocardial Ischemia / Q000517:prevention & control* / Q000628:therapy; D012008:Recurrence
D002121:Calcium Channel Blockers